Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women

References

• Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome – risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157–62.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferruci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562–8.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29–36.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151–8.
   PubMed Web of Science ®Google Scholar
• Uzun H, Zorba OÜ. Metabolic syndrome in female patients with overactive bladder. Urology 2012;79:72–5.
   PubMed Web of Science ®Google Scholar
• Tong YC, Cheng JT. Alterations of M2, 3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol 2007;178:1537–42.
   PubMedGoogle Scholar
• Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J Urol 2008;179:2470–6.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469–80.
   PubMed Web of Science ®Google Scholar
• Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012;2012: Article ID 145754.
   PubMedGoogle Scholar
• Cohen JC, Horto JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519–23.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202–19.
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Feeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4–20.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987–1000.
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–21.
   PubMed Web of Science ®Google Scholar
• Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC. Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol 2011;185:571–8.
   PubMed Web of Science ®Google Scholar
• Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009;182:616–14.
   PubMed Web of Science ®Google Scholar
• Nseir W, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011;56:3439–49.
   PubMed Web of Science ®Google Scholar
• Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stansyzk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599–604.
   PubMed Web of Science ®Google Scholar
• Hubeaux K, Deffieux X, Raibaut P, Le Breton F, Jousse M, Amaraneco G. Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome. Neurourol Urodyn 2011;30:1467–72.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4–12.
   PubMed Web of Science ®Google Scholar
• Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2012;171:571–82.
   Google Scholar
• Kessler OJ, Keisari Y, Servadio C, Abramovic A. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 1998;159:1049–53.
   PubMed Web of Science ®Google Scholar
• Kupelian V, Rosen RC, Roehrborn CG, Tyagi P, Chancellor MB, McKinlay JB. Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) survey. BJU Int 2012;110:401–7.
   PubMedGoogle Scholar
• Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willet WC, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 1998;158:2349–56.
   PubMedGoogle Scholar
• Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103–7.
   PubMed Web of Science ®Google Scholar
• Strauss S, Gavish E, Gottlieb P, Katsnelson L. Inter-observer and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007;189:320–3.
   Web of Science ®Google Scholar